Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...

The drug was 88% effective against the need for medical attention among those in their second respiratory virus season.

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Some Alberta doctors are calling on the provincial government to make an injection designed to protect newborns from severe ...

The good news: In October, a new preventive medicine, the monoclonal antibody Nirsevimab, became available to babies and at-risk toddlers to help protect them from RSV (Respiratory Syncytial Virus).

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically ...

Infants will be able to receive a free immunisation to protect them against serious illness from respiratory syncytial virus (RSV), under a new $16.6 million NSW Government RSV prevention program to ...

They also may have implications for when the RSV monoclonal antibody, Nirsevimab, should be administered to newborns. Similar research should be conducted for other vaccines administered during ...

RSV, which stands for respiratory syncytial ... young children between 8 and 19 months of age also receive a dose of nirsevimab or palivizumab to protect them during their second RSV season.